211 related articles for article (PubMed ID: 18391223)
1. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Horwitz KB; Dye WW; Harrell JC; Kabos P; Sartorius CA
Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5774-9. PubMed ID: 18391223
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
Kabos P; Haughian JM; Wang X; Dye WW; Finlayson C; Elias A; Horwitz KB; Sartorius CA
Breast Cancer Res Treat; 2011 Jul; 128(1):45-55. PubMed ID: 20665103
[TBL] [Abstract][Full Text] [Related]
3. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.
Axlund SD; Yoo BH; Rosen RB; Schaack J; Kabos P; Labarbera DV; Sartorius CA
Horm Cancer; 2013 Feb; 4(1):36-49. PubMed ID: 23184698
[TBL] [Abstract][Full Text] [Related]
4. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
[TBL] [Abstract][Full Text] [Related]
5. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.
Yoo BH; Axlund SD; Kabos P; Reid BG; Schaack J; Sartorius CA; LaBarbera DV
J Biomol Screen; 2012 Oct; 17(9):1211-20. PubMed ID: 22751729
[TBL] [Abstract][Full Text] [Related]
6. Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.
Knox AJ; Scaling AL; Pinto MP; Bliesner BS; Haughian JM; Abdel-Hafiz HA; Horwitz KB
Breast Cancer Res; 2014 Aug; 16(4):418. PubMed ID: 25116921
[TBL] [Abstract][Full Text] [Related]
7. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
8. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.
Finlay-Schultz J; Cittelly DM; Hendricks P; Patel P; Kabos P; Jacobsen BM; Richer JK; Sartorius CA
Oncogene; 2015 Jul; 34(28):3676-87. PubMed ID: 25241899
[TBL] [Abstract][Full Text] [Related]
9. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
10. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases.
Joensuu K; Leidenius M; Kero M; Andersson LC; Horwitz KB; Heikkilä P
Breast Cancer (Auckl); 2013; 7():23-34. PubMed ID: 23514931
[TBL] [Abstract][Full Text] [Related]
11. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.
Fettig LM; McGinn O; Finlay-Schultz J; LaBarbera DV; Nordeen SK; Sartorius CA
Oncogene; 2017 Nov; 36(44):6074-6084. PubMed ID: 28692043
[TBL] [Abstract][Full Text] [Related]
12. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
Sartorius CA; Harvell DM; Shen T; Horwitz KB
Cancer Res; 2005 Nov; 65(21):9779-88. PubMed ID: 16266999
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.
Chuthapisith S; Permsapaya W; Warnnissorn M; Akewanlop C; Sirivatanauksorn V; Prasarttong Osoth P
Asian Pac J Cancer Prev; 2012; 13(2):459-62. PubMed ID: 22524806
[TBL] [Abstract][Full Text] [Related]
14. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.
Haughian JM; Pinto MP; Harrell JC; Bliesner BS; Joensuu KM; Dye WW; Sartorius CA; Tan AC; Heikkilä P; Perou CM; Horwitz KB
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2742-7. PubMed ID: 21969591
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
17. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract][Full Text] [Related]
18. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
